A Pennsylvania jury has decided lawsuits filed against a New Jersey drug maker by two former users of the diet drug Pondimin.
Wyeth, in a statement issued Tuesday night, said the jury ruled in its favor in one case and awarded the other plaintiff $48,000 in compensatory damages.
Both had claimed they suffered heart valve damage from using the drug, which was part of the once wildly popular fen-phen combination.
FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane
FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts
Pondimin and the other drug, Redux, were pulled from the market in September 1997 amid reports they had caused heart valve damage and, in a small number of users, a potentially deadly lung condition.
The verdict comes just days after Madison, N.J.-based Wyeth and attorneys for former fen-phen users seeking compensation under a national class-action settlement announced a deal in which they would get payments from a settlement trust fund sooner but would receive less money.
FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane
FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts
That agreement, though, must still be approved by a federal judge after some details are resolved during the next few weeks.
According to court documents, the deal announced last Thursday requires Wyeth to add $1.275 billion to the $3.75 billion trust fund it set up to cover the settlement.
Wyeth has already reserved $16.6 billion to cover the trust fund, legal fees, jury awards and out-of-court settlements, as well as the lung damage cases, but only $3.3 billion remains in the fund.














